Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer

Next Previous
X
Search
Trial Profile

ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Carboplatin; Docetaxel; Paclitaxel
  • Indications Adenocarcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALTTO
  • Sponsors GlaxoSmithKline; GSK; Novartis; Novartis Pharma KK; Novartis Pharmaceuticals

    • Most Recent Events

    • 01 Feb 2024 Results of sub analysis assessing whether erythropoiesis-stimulating agents (ESA) administration impacts the outcomes of patients with HER2-positive early breast cancer, published in the Breast Cancer Research and Treatment
    • 13 Sep 2022 Results identifying biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab, presented at the 47th European Society for Medical Oncology Congress.
    • 01 Sep 2022 Results of sub analysis (n=2821 ) exploring the long-term outcomes of patients with small node-negative tumours published in the British Journal of Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top